© Copyright Acquisition International 2024 - All Rights Reserved.

Article Image - Changing Perception On Collecting Information
Posted 28th January 2020

Changing Perception On Collecting Information

Conventionally, data mining in biomedicine in the ‘omics’ era refers to a bioinformatics approach that combines key concepts of biology with advanced computer tools or statistical methods that are primarily used to discover, select and prioritize targets. 4HF Biotec is one of the rare companies that has established a novel data mining platform by unifying multiple sources of data for drug discovery in cancer. Winning the award for Germany’s Most Innovative Cancer Data Analytics Company 2019, we profiled this exciting organization to discover more.

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Changing Perception On Collecting Information
4HF BIOTECH

Changing Perception On Collecting Information

Conventionally, data mining in biomedicine in the ‘omics’ era refers to a bioinformatics approach that combines key concepts of biology with advanced computer tools or statistical methods that are primarily used to discover, select and prioritize targets. 4HF Biotec is one of the rare companies that has established a novel data mining platform by unifying multiple sources of data for drug discovery in cancer. Winning the award for Germany’s Most Innovative Cancer Data Analytics Company 2019, we profiled this exciting organization to discover more.

Prof. Dr. Heinz-Herbert Fiebig founded 4HF Biotec in June 2015 following the acquisition of his previously founded organization, Oncotest, by Charles River Laboratories International.

In the 1980s, by his pioneering work in the field of cancer research at the University Medical Center Freiburg, his team demonstrated the closest resemblance of the Patient-derived xenograft (PDX) models with human cancer and postulated their suitability as best models for cancer drug testing. He founded Oncotest GmbH in the year 1993. The company specialized in in vivo pharmacology services, leveraging an extensive collection of more than 400 patient-derived xenografts (PDX) tumor models, as well as a full range of in vitro assays using both commercially available and proprietary PDXderived cell lines. After 22 years, in the year 2015, Oncotest GmbH was acquired by Charles River Laboratories International.

Driven by his motivation in exploring further into Cancer Drug Discovery and putting forward his decades-long research-derived data, he established 4HF Biotec.

“Using their fully functional data mining software, 4HF can run various programs to identify new small molecules that could be used in cancer treatments in the future.”

Traditionally, knowledge-based hypothesis-driven studies are the keyways for cancer therapeutic discoveries. Recently, in the ‘omics’ era, the advancement of the big data resources, catalyzed by breakthroughs in high-throughput technologies, has resulted in a paradigm shift in cancer therapeutic research. The combination of robust computational methods and genomics data has led to several successful clinical applications. However, a prerequisite to drug discovery decisions is the optimization of multiple parameters. Optimally connecting these parameters requires integrative information across multiple sources. However, it is a challenging and complex task to integrate information from disparate domains and the availability of a curated, connected, correlated and aligned platform is sparse.

Dr. Heinz-Herbert Fiebig
Founder of 4HF, Prof. Dr. Heinz-Herbert Fiebig

Specializing in Bioinformatics and Datamining, 4HF Biotec has curated, connected, aligned and correlated a wide assembly of cancer-related databases that will offer an unprecedented amount of information. The research team at 4HF has conducted a deeper data analysis, first analyzing the data from each platform separately and then combining them in an integrated cross-platform analysis. The unified database of 4HF Biotec contains data of several thousands of patient tumors and established models that have been annotated with millions of data points comprising drug sensitivity profiles (tested in vitro and in vivo) and molecular genetic characteristics (such as exome mutations, chromosomal aberrations/gene copy number variations and expression profiles). 

All the information available can then be used in analyzing various types of cancers and what type of genetic and transcriptomic perturbations they harbor. In addition, it allows anticipating the normal tissue toxicity which is of paramount interest as numerous drugs fail in clinical trials due to toxicity-related issues. By implementing specialized tools, widgets and statistical analyses it is possible to visualize data from the multiple sources in a single view thereby optimizing the process of target evaluation and facilitating R&D efforts in drug discovery.

Using their fully functional data mining software, 4HF can run various programs to identify new small molecules that could be used in cancer treatments in the future. Hundreds of cancer drugs have already been tested to these stringent standards, along with various mechanisms of action. The best candidates were evaluated in various drug combinations in a large variety of tumor models in vitro and in vivo to test real synergism or additivity. Biomarkers are a naturally occurring characteristic by which a particular process or progression of a disease can be identified, in this case, cancer. In addition, by identifying the appropriate biomarkers, it is possible to predict the treatment response and that would facilitate the decision of providing effective treatments. At 4HF, every new drug evaluation study includes an analysis of a biomarker profile, i.e., all relevant molecular genetic characters associated with drug sensitivities are systematically revealed using various statistical tests. By its in-built algorithms and predictive model it is possible to determine individual cancer susceptibility to therapies. The proprietary model developed by 4HF integrates tools to match and compare patient tumor information to preclinical models. Collectively, the use of 4HF’s proprietary platform and databases allow identifying targets across a spectrum of tumor types, assessing drug sensitivity and determining predictive biomarkers. In the future, this approach would have a scope to be applied in context of ‘Precision Medicine’, i.e., for precise information on targets in individual patient’s tumors, implying that the team can identify the tumors most likely to respond to a specific compound. In this way, cancer patients who are most likely to respond would be chosen and consequently, unnecessary treatment is avoided, increasing the chances of clinical trial success.

The future aim of 4HF Biotec includes development of more efficacious small molecule inhibitors and antibody-drug conjugates (ADCs) in Oncology as a joint venture with other experts from the field. To achieve this goal, as a first step, they have already identified several novel candidates to further develop that into ADCs. They further plan to out-license products and drug repurposing when applicable. In addition, their business model includes a CRO service to the Biotech and Pharmaceutical industries for identifying new targets in oncology, molecular analysis of known targets, identification of the sensitive tumor types in relation to the target and mechanism of action (MOA), discovery of biomarkers and drug profiling. 4HF Biotec is highly interested in establishing meaningful business collaboration with other experts from the industry and academia and always looking for new collaborators and investors.

Funding until recently has been by Founder and CEO Prof. Dr. Fiebig, allowing for the independent development of the methods and technology to the team’s specific agenda. Currently, plans are underway for the submission of a large grant asking for three million euros to the Ministry of Research and Technology in Germany. This would allow for significant development of the technologies that 4HF have already established, as well as beginning to explore other avenues.

“…cancer patients who are most likely to respond would be chosen and consequently, unnecessary treatment is avoided, increasing the chances of clinical trial success.”

Harnessing the power of data analytics, 4HF has managed to change the way in which we should analyze and interpret the information that can be collected. Drawing the strands that bind the various aspects of cancer data analytics together, it is possible to find out novel therapies for cancer. To this end, the data mining software has been perfected with its advanced features, the growth of the company is expected to follow. Piling innovation on innovation, 4HF’s search for investors could lead to a game-changing scenario. The future looks bright for this self-motivated company, drawing on new information to make novel and exciting discoveries.

Categories: Innovation


You Might Also Like
Read Full PostRead - Eye Icon
Managing Director of the Month
Leadership
04/05/2016Managing Director of the Month

Delivered Health Solutions Ltd provide high quality products and services for care homes that deal with cleaning as well as infection prevention and control.

Read Full PostRead - Eye Icon
Best Fund Administrator 2016 – Mauritius
Finance
08/06/2016Best Fund Administrator 2016 – Mauritius

CIM Global Business is the leading management company in Mauritius with over USD 150 billion in assets under administration with offices in both Mauritius and Singapore and a representative office in South Africa.

Read Full PostRead - Eye Icon
CEO of the Year – Wisconsin
Finance
02/02/2016CEO of the Year – Wisconsin

WEC Energy Group, Inc, (NYSE: WEC) is one of the nation’s premier energy companies, serving 4.4 million electric and natural gas customers in Wisconsin, Illinois, Michigan and Minnesota.

Read Full PostRead - Eye Icon
Seeing Advantages Where Others See Obstacles.
News
20/06/2023Seeing Advantages Where Others See Obstacles.

The family owned and operated business Custom Recycling has been awarded the title of South Carolina's Best Scrap Metal Recycling Company 2023.

Read Full PostRead - Eye Icon
Mind the Digital Gap
Innovation
18/06/2015Mind the Digital Gap

This viewpoint, written by Thibaut Jacquet-Lagreze, Head of Marketing & Sales HQ, Avaloq, focuses on the finance industry’s requirement to keep up with the digital transformation currently taking place. With the rise of fintechs becoming increasingly apparen

Read Full PostRead - Eye Icon
Technology Transactions
Innovation
29/06/2016Technology Transactions

As with many sectors, the value of technology transactions was impressive during the second half of 2015. In all USD 319,086 million-worth of deal making was recorded over the six months.

Read Full PostRead - Eye Icon
A Tenacious Portuguese Law Firm
Legal
20/07/2022A Tenacious Portuguese Law Firm

Under the hot Portuguese sun stands a no-nonsense, passionate law firm. Alves, Botelho, Varela & Associados provides advice across the legal spectrum and transgresses borders, offering its expertise to clients around the globe.

Read Full PostRead - Eye Icon
Setting Industry Standards
Innovation
12/03/2020Setting Industry Standards

An activity that was once exclusive to elite individuals has become an easily-accessible, readily available, and highly exciting venture for people across the world. Trading and investing has grown alongside technology to become an increasingly intuitive activ

Read Full PostRead - Eye Icon
Transparency, Integrity, Communication, Kindness
Corporate Social Responsibility
08/08/2022Transparency, Integrity, Communication, Kindness

Founded in 1996, Edkey Inc is a non-profit organisation which manages 28 schools and programmes across Arizona including 17 Sequoia Charter Schools. It works together with families to provide high quality educational services for their K-12 children by creatin



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow